The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.
Rena Buckstein
No relevant relationships to disclose
Michael Crump
No relevant relationships to disclose
Graeme A Fraser
No relevant relationships to disclose
Matthew C. Cheung
No relevant relationships to disclose
Eugenia Piliotis
No relevant relationships to disclose
Kevin Imrie
No relevant relationships to disclose
Vishal Kukreti
No relevant relationships to disclose
John Kuruvilla
No relevant relationships to disclose
Ralph M. Meyer
No relevant relationships to disclose
Jolanta Windsor
No relevant relationships to disclose
Gregory Russell Pond
No relevant relationships to disclose
Kathleen I. Pritchard
No relevant relationships to disclose
Mark Norman Levine
No relevant relationships to disclose